Antabio on quest to tackle antibiotic resistance
Antabio has administered the first dose of its antibiotic therapy for hospital acquired infections, to patients in a Phase I …
eFFECTOR reports interim data updates from cancer combo expansion cohort
eFFECTOR Therapeutics has reported positive interim data updates from a Phase II expansion cohort of zotatifin along with fulvestrant and …
Zentalis reports positive data from Phase Ib trial of cancer combo therapy
Zentalis Pharmaceuticals has reported positive data from a Phase Ib trial evaluating its WEE1 inhibitor, azenosertib combined with chemotherapy in …
FDA greenlights Neuralink for human trials
The US Food and Drug Administration (FDA) has approved Neuralink for its first in-human study. In a Twitter announcement, the …
Pfizer’s etrasimod aims to differentiate UC market with strong safety profile
The market for ulcerative colitis (UC) is filled with various treatment options, and the pipeline is relatively strong. The variety …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Oncolytics gears up for Phase III trial in HR+/HER2- breast cancer
Oncolytics Biotech is getting ready for a registrational Phase III clinical trial after announcing positive results from a Phase II …
Topas launches Phase IIa trial of celiac disease therapy
Topas Therapeutics has launched a Phase IIa clinical trial of TPM502 to treat patients with celiac disease, an autoimmune disorder. The …
Stallergenes Greer initiates Phase III study of Staloral Birch
Stallergenes Greer has initiated a Phase III clinical study of Staloral Birch to treat children and adolescents with birch pollen-induced …
BIAL R&D doses first patient in ACTIVATE study of BIA 28-6156
BIAL R&D has dosed the first patient in its Phase II ACTIVATE study of BIA 28-6156 to treat patients with …
Transgene and BioInvent report positive data for oncolytic virus
BioInvent International and Transgene’s partnership is looking optimistic following positive Phase 1a data on its oncolytic virus BT-001 for the …
Clarity completes first stage of prostate cancer trial
Clarity Pharmaceuticals is moving to the assessment of a second patient cohort for its Phase I/II theranostic trial, SECuRE. SECuRE (NCT04868604) …
Pharma industry mixed on outlook of decentralised trials
Decentralised clinical trials (DCTs) have been heralded as the clearcut future of pharma clinical research. But a panel of industry …
AbbVie and Genmab’s bispecific Epkinly has a first-to-market advantage in DLBCL
AbbVie and Genmab have announced accelerated FDA approval for their bispecific T-cell engager (BiTE) Epkinly (epcoritamab-bysp) for the treatment of …
Lynk doses first cohort in Phase Ib trial of psoriasis therapy
Lynk Pharmaceuticals has dosed the first cohort of patients in a Phase Ib clinical trial of LNK01004 ointment to treat …
Annexon reports topline results from Phase II trial of GA therapy
Annexon has reported topline results from its ARCHER Phase II clinical trial of ANX007 for the treatment of patients with …